← All trials
NCT01482559
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Jan 1, 2015
- Primary completion
- Jan 1, 2018
- Completion date
- Jan 1, 2018
- First posted
- —
- Last posted
- —
- Enrollment
- 830
- Arms / groups
- 2 / —
- Source
- AACT · pre-existing
Sponsors
- National University of IrelandLead sponsor
- Katholieke Universiteit LeuvenOverall official - principal investigator
- University of AlbertaOverall official - principal investigator
- Institut National de la Santé Et de la Recherche Médicale, FranceOverall official - principal investigator
- University of MontrealOverall official - principal investigator
- Royal College of Surgeons, IrelandOverall official - principal investigator
- University of LondonOverall official - principal investigator
- Coombe Women and Infants University HospitalOverall official - principal investigator
- Charles UniversityOverall official - principal investigator
- Royal College of Surgeons, IrelandCollaborator
- Katholieke Universiteit LeuvenCollaborator
- University of AlbertaCollaborator
- Institut National de la Santé Et de la Recherche Médicale, FranceCollaborator
- University of MontrealCollaborator
- University of AntwerpCollaborator
- National University of IrelandCollaborator
- University of LondonCollaborator
- Coombe Women and Infants University HospitalCollaborator
- National Maternity Hospital, IrelandCollaborator
- BrePco Biopharma LimitedCollaborator
- Clininfo S.A.Collaborator
- Charles UniversityCollaborator
- Queen's University, BelfastCollaborator
- National University of IrelandReponsible party - principal investigator
- National University of IrelandStudy director
- National University of IrelandOverall official - principal investigator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.